Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in India / NCT06818682
Recruiting Phase 2

Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial

NCT06818682 · tracked via the Priya Life Science India tracker
Sponsor
Tata Memorial Centre
Phase
Phase 2
Started
2025-02-17
Last updated
2025-02-21

Condition(s) studied

Prostate Carcinoma

Investigational drug(s) / intervention(s)

ADT for 9 months and ARTA for 6 monthsADT for 2 years

ADT for 9 months and ARTA for 6 months: Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 9 months and ARTA for 6 months

ADT for 2 years: Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 2 years

Study summary

Aim of the study to improve the treatment of high-risk non-metastatic prostate cancer by comparing reduced duration of hormone therapy to the standard duration of two years, when combined with curative intent standard of care radiotherapy to prostate and pelvic nodes. The reduced duration will be intensified with addition of newer hormonal agents such as abiraterone or enzalutamide tablets, which have been shown to improve disease control in locally advanced prostate cancer. This is hoped to reduce the side effects of prolonged hormone therapy, while maintaining similar rates of disease control and survival.

The effectiveness of both treatment approaches will be assessed in terms of cancer control, survival, and overall quality of life of patients. Additionally, the study will examine the side effects associated with each treatment regimen, which could provide valuable insights into impact of treatment duration on patients. If a person decides not to participate, they will still receive the standard two years of hormonal therapy and radiation therapy outside the study. This ensures that all patients receive appropriate care regardless of their involvement in the research. Participation is voluntary, and will not affect patient care.

Eligibility

Sex
MALE
Min age
19 Years
Max age
99 Years
Healthy volunteers
Accepted
Inclusion Criteria:- * Patients with biopsy proven prostate adenocarcinoma, deemed suitable for curative- intent radiotherapy * Clinicoradiological stage T1-T4N0M0 using PSMA-PETCT and MRI * High risk or very high risk (as per NCCN 2023): stage T3a + OR Gleason Score 4+4 or 4+5 OR PSA 20 + * Patient fit and able to receive ADT for 2 years * Patient fit and able to receive ARTA for 6 months * ECOG performance status 0-2 * Patient able and willing for informed consent and reliable for follow-up Exclusion Criteria:- * Primary Gleason pattern 5 (Gleason score 5+4 or 5+5) * Life expectancy deemed to be less than 2 years * Uncontrolled comorbidities such as diabetes or hypertension causing ineligibility to receive ARTA * Bulky primary disease with extensive infiltration into bladder/rectum/pelvic muscle * Prior ADT more than 3 months before screening or prior orchiectomy * Prior prostatectomy * Unsuitable for curative dose of radiotherapy (severe urinary obstructive symptoms, inflammatory bowel disease, prior pelvic radiotherapy etc.) * Presence of adverse pathological variants (such as small cell histology) * Unable or unwilling to consent and follow up

Primary outcome measure(s)

  • Disease-free survival (DFS), defined as the time to first clinicoradiological recurrence or death due to any cause, from the date of randomisation. — 5 years

Trial sites (1)

FacilityCityRegionStatus
Tata Memorial Centre Mumbai Maharashtra Recruiting

More Tata Memorial Centre trials in India

Bladder Cancer Adjuvant Radiotherapy Trial Active, not recruiting
Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) Recruiting
A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma Recruiting
Assessment of the Breast Cosmesis Using Deep Neural Networks: an Exploratory Study (ABCD) Recruiting
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06818682 on ClinicalTrials.gov ↗ ← All trials in India